If one of the three submission batches failed at accelerated condition,
is it necessary to initiating intermediate study?
|
1.According to “USFDA Guidance for industry ANDAs: Stability Testing
of Drug Substances and Products - Questions and Answers”
If
accelerated data show a significant change or failure of any attribute in one
or more batches, an applicant should submit intermediate data for all three batches.
In addition, the submission should contain a failure analysis (i.e.,
discussion concerning the observed failure(s)).
|
Pharma treasures is an informatory site, which shares pharma related articles. The ultimate goal of this site is to become a knowledge hub by gathering all pharma related technical information under one roof...... This blog mainly talks about QMS,cGMP,Regulatory Filings & Guidelines,Validation & Qualifications,Drug Stability,FDA 483s &Media Fill. Hope this blog will cater the needs of both fresher’s and experienced professionals.
Sunday, 2 February 2020
Stability Testing Question & Answers –If one of the three submission batches failed at accelerated condition, is it necessary to initiate intermediate study
Stability Testing Question & Answers; In-use Testing Requirements
How many batches shall be subjected for In-use stability
testing during stability study?
|
1.According to EMA Guidance “Note for Guidance on In-use Stability
Testing of Human Medicinal Products”
“A
minimum of two batches, at least pilot scale batches, should be subjected to
the test. At least one of the batches should be chosen towards the end of its
shelf life. If such results are not available, one batch should be tested at
the final point of the submitted stability studies”.
“If
the product is to be supplied in more than one container size or in different
strengths, the in-use stability test should be applied to the product which
presents the greatest susceptibility to change. The choice of the tested
product should always be justified”.
2.According to USFDA Guidance “ANDA Submissions — Content and
Format Guidance for Industry”
“One-time
in-use stability studies for oral liquids and other dosage forms (e.g., a
solution to be used within a certain period of opening the container per
labeling instructions, compatibility with a dropper when provided as part of
the container closure system), as applicable”.
|
Stability Testing Question & Answers –Antimicrobial Effectiveness Testing (AET) Requirements
The antimicrobial effectiveness test (previously known as the preservative effectiveness test),is a compendial test (antimicrobial test is described in USP <51>) performed during formulation development and stability testing of sterile parenteral multi-dose presentations of drug products that contain a preservative system.This test is intended to reproducible biological measurement of the activity of the preservative system in a product.
The
compendial AET tests of the USP and the European Pharmacopeia have very similar
methods, but they differ in sampling points and acceptance criteria.
How many batches shall be subjected for AET testing during stability
study?
|
1.According to “USFDA Guidance for industry ANDAs: Stability Testing
of Drug Substances and Products - Questions and Answers”
"One of
the primary batches of the drug product should be tested for antimicrobial
preservative effectiveness (in addition to preservative content) at the end
of the proposed shelf life. The drug product specification should include a
test for preservative content, and this attribute should be tested in all
stability studies".
|
Stability Testing Question & Answers –Container orientation
What is the recommended container orientatation of stability
samples (liquids, solutions,semi solids and suspensions) for US market ?
|
There
are two USFDA guidance’s, which gives inputs on container orientations during
stability study.
1.According to USFDA Guidance “ANDA Submissions — Content and
Format Guidance for Industry”
"For
primary batches of liquids, solutions, semi-solids, and suspensions, the
product should be placed into worst-case and non-worst-case scenarios. For
post-approval stability studies, the applicant should pick the worst-case
orientation for the study".
2.According to “USFDA Guidance for industry ANDAs: Stability
Testing of Drug Substances and Products - Questions and Answers”
"For
primary batches of liquids, solutions, semi-solids, and suspensions, the
product should be placed into an inverted (or horizontal) position and an
upright (or vertical) position. For routine stability studies, the applicant
should pick the worst case orientation for the study".
|
Subscribe to:
Posts (Atom)